[HTML][HTML] The blood-stage malaria antigen PfRH5 is susceptible to vaccine-inducible cross-strain neutralizing antibody

…, CA Long, FH Osier, K Marsh, AV Turner… - Nature …, 2011 - nature.com
Current vaccine strategies against the asexual blood stage of Plasmodium falciparum are
mostly focused on well-studied merozoite antigens that induce immune responses after …

My Life: Effects of a longitudinal, randomized study of self-determination enhancement on the transition outcomes of youth in foster care and special education

…, J Powers, S Pommier-Satya, A Turner… - Children and Youth …, 2012 - Elsevier
Youth in foster care disproportionately receive special education services and those in foster
care and special education are at compounded disadvantage as they attempt to transition …

[PDF][PDF] A PfRH5-based vaccine is efficacious against heterologous strain blood-stage Plasmodium falciparum infection in aotus monkeys

…, AJ Spencer, KA Hjerrild, DGW Alanine, AV Turner… - Cell host & …, 2015 - cell.com
Antigenic diversity has posed a critical barrier to vaccine development against the pathogenic
blood-stage infection of the human malaria parasite Plasmodium falciparum. To date, only …

Development of differential recognition for own-and other-race faces

JE Chance, AL Turner, AG Goldstein - The Journal of psychology, 1982 - Taylor & Francis
Subjects (N = 106) ranging in age from six to 20 years performed two face-recognition tasks—one
with Caucasians' photo portraits and one with Orientals'. Although the youngest …

TAKE CHARGE for the future: A controlled field-test of a model to promote student involvement in transition planning

LE Powers, A Turner, D Westwood… - Career …, 2001 - journals.sagepub.com
This study investigated the efficacy of an intervention model to promote student involvement
in transition planning. The intervention included the coaching of youths in the application of …

Phase I Trial of the PARP Inhibitor Olaparib and AKT Inhibitor Capivasertib in Patients with BRCA1/2- and Non–BRCA1/2-Mutant Cancers

…, S Ward, R Matthews, M Parmar, A Turner… - Cancer discovery, 2020 - AACR
In the first trial to combine PARP and AKT inhibitors, a prospective intrapatient dose- escalation
design demonstrated safety, tolerability, and pharmacokinetic–pharmacodynamic activity …

An affinity-enhanced, broadly neutralizing heavy chain–only antibody protects against SARS-CoV-2 infection in animal models

…, A Popplewell, M Ellis, K Brady, A Turner… - Science Translational …, 2021 - science.org
Broadly neutralizing antibodies are an important treatment for individuals with coronavirus
disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS…

Plasma creatinine rises dramatically in the first 48 hours of life in preterm infants

LS Miall, MJ Henderson, AJ Turner, KG Brownlee… - …, 1999 - publications.aap.org
Objective. Published data show that plasma creatinine falls steadily during the first 28 days
of life and that creatinine levels in the neonatal period are higher in more premature infants. …

Generation and characterization of a high affinity anti-human FcRn antibody, rozanolixizumab, and the effects of different molecular formats on the reduction of plasma …

…, O Qureshi, K Sarkar, SP Shaw, R Tewari, A Turner… - MAbs, 2018 - Taylor & Francis
Rozanolixizumab (UCB7665), a humanized high-affinity anti-human neonatal Fc receptor (FcRn)
monoclonal antibody (IgG4P), has been developed to reduce pathogenic IgG in …

[HTML][HTML] Targeting myeloid chemotaxis to reverse prostate cancer therapy resistance

…, C Yap, R Matthews, H Badham, T Prout, A Turner… - Nature, 2023 - nature.com
Inflammation is a hallmark of cancer 1 . In patients with cancer, peripheral blood myeloid
expansion, indicated by a high neutrophil-to-lymphocyte ratio, associates with shorter survival …